Cover Image
市場調查報告書

過敏症:開發中產品分析

Hypersensitivity - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 302488
出版日期 內容資訊 英文 313 Pages
訂單完成後即時交付
價格
Back to Top
過敏症:開發中產品分析 Hypersensitivity - Pipeline Review, H2 2016
出版日期: 2016年09月28日 內容資訊: 英文 313 Pages
簡介

所謂過敏症,是指由正常的免疫系統引起的過剩、不良的反應。產生發冷、身體的疼痛、胸部壓迫感、咳嗽的惡化、呼吸急促、疲勞感、體重減少等症狀。可使用類固醇劑和H1及H2受體拮抗劑等。

本報告提供過敏症的治療藥的開發情形調查分析,開發中產品的概要,臨床實驗的各階段的產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

過敏症概要

治療藥的開發

開發中的治療藥:各企業

各調查中的治療藥:各大學/研究機關

開發中產品的概要

開發中的產品:各企業

各調查中的產品:各大學/研究機關

開發治療藥的企業

治療藥的評估

藥物簡介

暫停的計劃

開發中止的產品

產品開發里程碑

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8499IDB

Summary

Global Markets Direct's, 'Hypersensitivity - Pipeline Review, H2 2016', provides an overview of the Hypersensitivity pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hypersensitivity, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hypersensitivity and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Hypersensitivity
  • The report reviews pipeline therapeutics for Hypersensitivity by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Hypersensitivity therapeutics and enlists all their major and minor projects
  • The report assesses Hypersensitivity therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Hypersensitivity

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Hypersensitivity
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Hypersensitivity pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
  • Introduction
  • Hypersensitivity Overview
  • Therapeutics Development
  • Hypersensitivity - Therapeutics under Development by Companies
  • Hypersensitivity - Therapeutics under Investigation by Universities/Institutes
  • Hypersensitivity - Pipeline Products Glance
  • Hypersensitivity - Products under Development by Companies
  • Hypersensitivity - Products under Investigation by Universities/Institutes
  • Hypersensitivity - Companies Involved in Therapeutics Development
  • Hypersensitivity - Therapeutics Assessment
  • Drug Profiles
  • Hypersensitivity - Dormant Projects
  • Hypersensitivity - Discontinued Products
  • Hypersensitivity - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Hypersensitivity, H2 2016
  • Number of Products under Development for Hypersensitivity - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Development by Companies, H2 2016 (Contd..2)
  • Number of Products under Development by Companies, H2 2016 (Contd..3)
  • Number of Products under Development by Companies, H2 2016 (Contd..4)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Development by Companies, H2 2016 (Contd..3)
  • Products under Development by Companies, H2 2016 (Contd..4)
  • Products under Development by Companies, H2 2016 (Contd..5)
  • Products under Development by Companies, H2 2016 (Contd..6)
  • Products under Development by Companies, H2 2016 (Contd..7)
  • Products under Development by Companies, H2 2016 (Contd..8)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Hypersensitivity - Pipeline by Adamis Pharmaceuticals Corporation, H2 2016
  • Hypersensitivity - Pipeline by Adverum Biotechnologies, Inc., H2 2016
  • Hypersensitivity - Pipeline by Aimmune Therapeutics, Inc., H2 2016
  • Hypersensitivity - Pipeline by Alfacyte Ltd, H2 2016
  • Hypersensitivity - Pipeline by ALK-Abello A/S, H2 2016
  • Hypersensitivity - Pipeline by Allakos Inc., H2 2016
  • Hypersensitivity - Pipeline by Allergopharma GmbH & Co. KG, H2 2016
  • Hypersensitivity - Pipeline by Allergy Therapeutics Plc, H2 2016
  • Hypersensitivity - Pipeline by Amgen Inc., H2 2016
  • Hypersensitivity - Pipeline by Anacor Pharmaceuticals, Inc., H2 2016
  • Hypersensitivity - Pipeline by AnaptysBio, Inc., H2 2016
  • Hypersensitivity - Pipeline by Anergis SA, H2 2016
  • Hypersensitivity - Pipeline by Antigen Express, Inc., H2 2016
  • Hypersensitivity - Pipeline by Aravax Pty Ltd, H2 2016
  • Hypersensitivity - Pipeline by Array BioPharma Inc., H2 2016
  • Hypersensitivity - Pipeline by ASIT biotech s.a., H2 2016
  • Hypersensitivity - Pipeline by AskAt Inc., H2 2016
  • Hypersensitivity - Pipeline by Astellas Pharma Inc., H2 2016
  • Hypersensitivity - Pipeline by BioLingus AG, H2 2016
  • Hypersensitivity - Pipeline by Biomay AG, H2 2016
  • Hypersensitivity - Pipeline by Biotec Pharmacon ASA, H2 2016
  • Hypersensitivity - Pipeline by Boehringer Ingelheim GmbH, H2 2016
  • Hypersensitivity - Pipeline by Circassia Pharmaceuticals Plc, H2 2016
  • Hypersensitivity - Pipeline by DBV Technologies S.A., H2 2016
  • Hypersensitivity - Pipeline by DNJ Pharma, Inc., H2 2016
  • Hypersensitivity - Pipeline by EA Pharma Co Ltd, H2 2016
  • Hypersensitivity - Pipeline by Enzene Biosciences Ltd., H2 2016
  • Hypersensitivity - Pipeline by EpiVax, Inc., H2 2016
  • Hypersensitivity - Pipeline by Fountain Biopharma Inc., H2 2016
  • Hypersensitivity - Pipeline by HAL Allergy BV, H2 2016
  • Hypersensitivity - Pipeline by iCeutica, Inc., H2 2016
  • Hypersensitivity - Pipeline by ImmunoFrontier, Inc., H2 2016
  • Hypersensitivity - Pipeline by Immunomic Therapeutics, Inc., H2 2016
  • Hypersensitivity - Pipeline by Immupharma Plc, H2 2016
  • Hypersensitivity - Pipeline by InMed Pharmaceuticals Inc., H2 2016
  • Hypersensitivity - Pipeline by Interprotein Corporation, H2 2016
  • Hypersensitivity - Pipeline by Japan Tobacco Inc., H2 2016
  • Hypersensitivity - Pipeline by JW Pharmaceutical Corporation, H2 2016
  • Hypersensitivity - Pipeline by Laboratorios LETI S.L., H2 2016
  • Hypersensitivity - Pipeline by Monosol Rx, LLC, H2 2016
  • Hypersensitivity - Pipeline by NAL Pharmaceuticals Ltd., H2 2016
  • Hypersensitivity - Pipeline by Neovacs SA, H2 2016
  • Hypersensitivity - Pipeline by Novartis AG, H2 2016
  • Hypersensitivity - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016
  • Hypersensitivity - Pipeline by Regeneron Pharmaceuticals Inc, H2 2016
  • Hypersensitivity - Pipeline by REGiMMUNE Corporation, H2 2016
  • Hypersensitivity - Pipeline by Roxall Medizin GmbH, H2 2016
  • Hypersensitivity - Pipeline by Sanofi, H2 2016
  • Hypersensitivity - Pipeline by Sealife PHARMA GMBH, H2 2016
  • Hypersensitivity - Pipeline by Stallergenes Greer plc, H2 2016
  • Hypersensitivity - Pipeline by Stallergenes SAS, H2 2016
  • Hypersensitivity - Pipeline by Swecure AB, H2 2016
  • Hypersensitivity - Pipeline by Therabron Therapeutics, Inc., H2 2016
  • Hypersensitivity - Pipeline by Thesan Pharmaceuticals, Inc., H2 2016
  • Hypersensitivity - Pipeline by Toleranzia AB, H2 2016
  • Hypersensitivity - Pipeline by United Biomedical, Inc., H2 2016
  • Hypersensitivity - Pipeline by United BioPharma, Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Hypersensitivity - Dormant Projects, H2 2016
  • Hypersensitivity - Dormant Projects (Contd..1), H2 2016
  • Hypersensitivity - Dormant Projects (Contd..2), H2 2016
  • Hypersensitivity - Dormant Projects (Contd..3), H2 2016
  • Hypersensitivity - Dormant Projects (Contd..4), H2 2016
  • Hypersensitivity - Dormant Projects (Contd..5), H2 2016
  • Hypersensitivity - Dormant Projects (Contd..6), H2 2016
  • Hypersensitivity - Dormant Projects (Contd..7), H2 2016
  • Hypersensitivity - Dormant Projects (Contd..8), H2 2016
  • Hypersensitivity - Dormant Projects (Contd..9), H2 2016
  • Hypersensitivity - Dormant Projects (Contd..10), H2 2016
  • Hypersensitivity - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Hypersensitivity, H2 2016
  • Number of Products under Development for Hypersensitivity - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Top 10 Routes of Administration, H2 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2016
  • Number of Products by Top 10 Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top